Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma - Wikidata - thesis-toulmin - TriplyDB

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

http://www.wikidata.org/entity/Q34372972

about

Leaving the lysosome behind: novel developments in autophagy inhibition Targeting autophagy in cancer management - strategies and developments You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia Autophagy in cancer Autophagy in malignant transformation and cancer progression Emerging strategies to effectively target autophagy in cancer Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'Autophagy- An emerging target for melanoma therapy Therapeutic Targeting of Autophagy Modulation of inflammation by autophagy: Consequences for human disease Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy.A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma Autophagy: In the cROSshairs of cancer.Involvement of autophagy inhibition in Brucea javanica oil emulsion-induced colon cancer cell death.Molecular pathways: autophagy in cancer--a matter of timing and context.Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells.Autophagy and its effects: making sense of double-edged swords.Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers.Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion.Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities.Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia High-dose chloroquine is metabolically cardiotoxic by inducing lysosomes and mitochondria dysfunction in a rat model of pressure overload hypertrophy.Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease.Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shRNA screening.Chloroquine Sensitizes Nasopharyngeal Carcinoma Cells but Not Nasoepithelial Cells to Irradiation by Blocking Autophagy Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.Elevated autophagy gene expression in adipose tissue of obese humans: A potential non-cell-cycle-dependent function of E2F1.BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.Significantly enhanced tumor cellular and lysosomal hydroxychloroquine delivery by smart liposomes for optimal autophagy inhibition and improved antitumor efficiency with liposomal doxorubicin Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin.Recent insights into the function of autophagy in cancer.Aquaporin 3 facilitates chemoresistance in gastric cancer cells to cisplatin via autophagy.

P2860

Q26774549-5E214B10-943A-44A4-BED8-0DA3340E710B Q26782468-15A6464B-76ED-4F08-94A1-38E469606800 Q26998971-0AC940C9-7F80-4C16-A0AF-5BE6DD3863C6 Q26999216-D0B23548-7703-46B3-B225-64EF5FAFF0F9 Q27000191-29FAF030-A84B-45D0-AEBC-B25F527D489C Q27009194-7CDD7146-5FE4-4CD0-A63F-B98BA46C6586 Q27022240-BFDB575C-7779-4777-80A7-847A8D64DE46 Q28067399-0446A0EE-8CEA-4BEC-8768-00FF58CB6456 Q28071400-E78CF9EE-99E8-4862-A21B-04583937CD69 Q28078117-8AAFAC3C-9CF1-457F-9A89-08157591C7B5 Q28082840-8C6AF450-E622-4723-916B-A5C03C5A0E05 Q30646716-998EA360-FBBE-4737-B8D8-6D23FE59DAA1 Q33416266-3D378888-E544-4590-BA8A-0F02BB0F262E Q33422577-95E230E9-446F-499F-B5DF-A4A4AA0232DD Q33746474-67C0A5FA-E00F-4130-9BC0-1507D573FB5F Q34372977-36FC229B-71AD-4464-8A61-055B0A6AD2CD Q34372987-4F3A66DC-C217-4802-9410-15A47C3B140B Q34372994-DD3C2BA3-BC91-4E40-AEE3-0D61742D93E7 Q34373001-CA622327-2F03-4703-B113-A0183E315D0D Q34543548-84C6788D-7D9E-444D-99E0-2A2618AF81ED Q35042237-CDBB5788-551B-4447-BE12-852980A6FABF Q35044465-ED6BAD8A-739F-4E31-AD9C-88E0297374E2 Q35086734-936A40FC-2CA3-4C74-B5ED-6E980AEAED8F Q35330324-8D0956B4-AB34-4CDD-86DE-28597A4C5F01 Q35408800-D52AD9D6-BC50-4171-9130-E881FDADFC8A Q35434206-A97871D5-8DE1-4405-8897-F57522B59393 Q35609829-E5984E32-6B2E-4F3D-A60D-70E7A397F068 Q35824343-29E03742-F7D8-43CE-8EED-7FCB93DEE70F Q35852817-0FF16B13-9266-4D90-81C7-74DAE3485FD8 Q36004316-BAA6FAE2-4C2D-4456-AF1C-99932141F4FB Q36031947-3F05239B-D199-4B69-B696-879FEEF8B0DF Q36069096-5041EA15-500B-463C-B2AD-4031E7B6B80A Q36208147-C30A2156-24A6-46AE-B113-3AA69CA60DC5 Q36329393-C06C532A-4E1B-48F8-883C-8238A01F962E Q36777283-F8E80201-4E4D-4705-9494-46C2C0010C39 Q36962548-16005B45-60B6-4B3C-839E-C87E34EAE458 Q37041531-39DDB5E3-8491-45B6-A2AD-F6D2F39CDBCD Q37295253-854C0A07-99DC-455C-A176-7E9E31F5B9B9 Q37343004-4BF85417-B12A-4BE9-B9DF-449D3E8F21C7 Q37412002-D2C824E4-7C2C-4C6F-9577-03CF25D73090

P2860

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

http://www.wikidata.org/entity/Q34372972

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@ast

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@en

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@nl

type

label

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@ast

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@en

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@nl

prefLabel

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@ast

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@en

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@nl

P1433

Q34372972-FF317264-5076-4246-900B-45C0AE12E963

P1476

Q34372972-D1053ABE-6141-4F0F-9782-8FD4B2D779DA

P2093

Q34372972-0FB69F33-137F-4957-84DD-C90832BB4C1C

Q34372972-1582CD95-EA5C-42D6-AC33-988BCB5DA0F5

Q34372972-2B7274BC-512F-4B36-ABAC-6BED4E575DDB

Q34372972-35E042FC-5A8D-4833-A268-A28204B12D64

Q34372972-4FF15F93-BE8A-4A8B-978B-047F5AE59AB1

Q34372972-65F3F541-A580-437C-B0EF-65F3136B23DB

Q34372972-6B9E06EF-D761-402B-A38A-167E9A17E527

Q34372972-70068112-CAB9-4301-B968-23B39555ED23

Q34372972-7B27E02B-2892-4D2C-B646-EFF403587E3A

Q34372972-9A1BACBC-9FF3-44FB-8E31-F217963D02CA

P2860

Q34372972-05736C3C-F011-498A-AB29-D23FC21DBEBF

Q34372972-1D8D34CF-DC71-47E0-8799-2BFF8F82A77F

Q34372972-1E126747-A75B-414F-BB7B-5F700C082B07

Q34372972-2A1F6188-1194-4FA2-9EA7-196BD074B8DB

Q34372972-2E055F90-8A9F-4D91-8DED-3982221CEBE3

Q34372972-52B68582-6402-4DE8-BFE9-AE7275E8E104

Q34372972-535F817C-62F6-44E7-B8CF-7E4190B5C99F

Q34372972-5CD1D9E6-9CC6-4972-AB7F-9D67192DEA03

Q34372972-5E9C8E64-9CEB-44BE-A51F-A2A7EC1E3DBD

Q34372972-61677915-D2A3-4CE0-AEDC-FD1662F87B7C

P304

Q34372972-CE0704A4-322A-41E4-BAE3-C59E13C281ED

P31

Q34372972-F27AD3E6-6D47-4D3D-B629-75462C2E38B3

P356

Q34372972-A6B65A53-8FCC-4EFB-8CEC-389CBE7A63A9

P433

Q34372972-F4A8ADE0-D1BB-4906-A571-FECF74277312

P478

Q34372972-1F8C0909-18AF-4410-B849-5D3FECAEFE29

P50

Q34372972-4B2E9965-5D38-4E64-BBC4-622B071EF3E9

Q34372972-FC400333-72C6-4140-901D-3AA1D3C6264A

P577

Q34372972-2A8C94A7-B56F-4DAA-9E31-6EB7F68D8070

P5875

Q34372972-75D2ABD6-8DD7-4AD9-903A-560EB6BD9E25

P698

Q34372972-19BB9FEF-5F58-4421-A408-C978FEADBD5E

P921

Q34372972-30A0C496-4AEB-4FF5-A24F-05D1287CCEB2

Q34372972-65B67F8F-AF81-41DA-8B3B-A0E623D0E05C

Q34372972-69A0C7F1-536A-49AD-8C9A-1D408684A7FC

P932

Q34372972-D3A08EBC-DFE1-4341-9963-460DEBB7AD8F

P356

P1433

P1476

Phase I trial of hydroxychloro ...... nced solid tumors and melanoma

@en

P2093

Amy Kramer

http://www.w3.org/2001/XMLSchema#string

Angela M DeMichele

http://www.w3.org/2001/XMLSchema#string

Daniel F Heitjan

http://www.w3.org/2001/XMLSchema#string

Glenda Rodgers

http://www.w3.org/2001/XMLSchema#string

Jonathon Kaiser

http://www.w3.org/2001/XMLSchema#string

Kay-See Tan

http://www.w3.org/2001/XMLSchema#string

Laura Pontiggia

http://www.w3.org/2001/XMLSchema#string

Leslie A Fecher

http://www.w3.org/2001/XMLSchema#string

Lisa E Davis

http://www.w3.org/2001/XMLSchema#string

Lynn M Schuchter

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Pancreatic cancers require autophagy for tumor growth

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma

Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients.

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.

Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.

Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.

P304

1369-1379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/AUTO.29118

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Katherine L Nathanson

Andrea B Troxel

P577

2014-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263711387

http://www.w3.org/2001/XMLSchema#string

P698

24991839

http://www.w3.org/2001/XMLSchema#string

P921

hydroxychloroquine

phase I clinical trial

P932

4203514

http://www.w3.org/2001/XMLSchema#string